Manforce Condoms

Delhi, India Founded: 2012 • Age: 14 yrs Listed
Condom manufacturing and sexual health resources in India.
Request Access
Report Incorrect Data
Page last updated

About Manforce Condoms

Manforce Condoms is a publicly listed company based in Delhi (India) founded in 2012. Condom manufacturing and sexual health resources in India. The company has 19,928 employees. Its website manforcecondoms.com draws about 48 thousand monthly visits. Its Indian entity Mankind Pharma Limited reported revenue of ₹14,648 Cr. Manforce Condoms offers products and services including Condoms and Sexual Health Education. Its focus areas include Reproductive Health, Contraceptives, Condom Manufacturing and Education and Information.

Company details

Manforce is identified as a prominent condom brand in India, with sales data indicating widespread distribution and usage. Educational content on condom safety, usage guidelines, and related topics is provided through blogs and FAQs, which are accessed by users seeking reliable information. The brands products are marketed online and through retail channels, emphasizing prevention of unintended pregnancies and health risks. This approach is supported by expert advice and resources that address common concerns in sexual health, ensuring accessibility for consumers.

  • Headquarters Delhi, India
  • Employees 19,928
  • Stage Public
  • Sectors
    Healthcare
  • Website category Gambling · Sports Betting
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Social X Facebook Instagram YouTube
  • Legal Name Mankind Pharma Limited
  • Date of Incorporation 03 Jul, 1991
  • Jurisdiction New Delhi, Delhi, India
Operational Areas
Healthcare → Pharmaceuticals & Distribution
Healthcare → Women's Health & Fertility
Key Metrics
  • Market Cap
    ₹91,390 Cr

    MANKIND · NSE

  • Share Price
    ₹2,312.00

    +4.49% today

  • Revenue
    ₹14,278 Cr

    FY 2025-26 · +17.0% YoY

  • EBITDA
    ₹3,493 Cr

    Margin 24.5%

  • Net Profit
    ₹2,014 Cr

    FY 2025-26 · +12.2% YoY

  • P/E (TTM)
    42.8x

    P/B 5.6x

  • ROE
    12.7%

    ROCE 13.0%

  • Debt / Equity
    0.48

    Interest cover 24.7x

  • Employee Count
    19,928

Products & Services of Manforce Condoms

Manforce Condoms offers a comprehensive portfolio of products and services, including Condoms and Sexual Health Education.

Condoms
Contraceptives

Condoms are provided as essential protective barriers during sexual activities to prevent pregnancies and infections

Sexual Health Education
Informational Services

Educational resources on condom use and related topics are offered through blogs and FAQs to promote awareness

Apps and channels of Manforce Condoms

its YouTube channel Manforce Condoms has 107K subscribers and 30 videos.

Manforce Condoms
YouTube 107K subscribers 30 videos Film & Animation
Open channel

Videos from Manforce Condoms

The most watched videos on Manforce Condoms's YouTube channel, Manforce Condoms (107K subscribers). Click a video to play it here.

Partner's Choice, Karo Prioritise | #ApnePartnerSePucho | Kartik Aaryan | Manforce Condoms | Hindi
22.6M views
#CondomNahiManforceBolo | Feat. Dolly Singh
10.2M views
Manforce Condoms Ft. Gaurav Kapoor | #PyaarMeinHIGH - Valentine’s Day Video
3.9M views
Manforce Condoms | Busting Myths about Masturbation ft. Dr. Prakash Kothari | Episode 3
968K views

More on Manforce Condoms.

Board of directors of Mankind Pharma Limited (Manforce Condoms)

Mankind Pharma Limited is the primary company behind Manforce Condoms. The board of Mankind Pharma Limited currently have 8 directors; the longest-serving is Ramesh Juneja, appointed in 1991. 19 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Ramesh Juneja
DIN 00283399
Whole-time director03 Jul 199135 yrs 3 moMankind Pharma Limited
Rajeev Juneja
DIN 00283481
Managing Director22 Dec 199233 yrs 10 moMankind Pharma Limited
Sheetal Arora
DIN 00704292
Whole-time director21 Sep 200719 yrs 1 moMankind Pharma Limited
Satish Kumar Sharma
DIN 07615602
Whole-time director23 Sep 201610 yrs 1 moMankind Pharma Limited
Tilokchand Punamchand Ostwal
DIN 00821268
Director01 Jan 20206 yrs 9 moMankind Pharma Limited
Vijaya Sampath
DIN 00641110
Director01 Aug 20224 yrs 2 moMankind Pharma Limited
Vivek Kalra
DIN 00426240
Director01 Aug 20224 yrs 2 moMankind Pharma Limited
Anish Vanraj Bafna
DIN 02925792
Director10 Aug 20262 moMankind Pharma Limited

IPO & Listings of Manforce Condoms

Manforce Condoms is a publicly listed company on the NSE with ticker symbol MANKIND in India, operating in the Pharmaceuticals sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • Listed onNSE: MANKIND
  • Listed entityMankind Pharma Limited
  • Exchange sectorPharmaceuticals

Financials of Manforce Condoms

Exchange-reported figures of Mankind Pharma Limited, the listed company behind Manforce Condoms (NSE: MANKIND).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹14,278 Cr
+17.0% YoY
EBITDA
₹3,493 Cr
+15.6% YoY
Profit After Tax
₹2,014 Cr
+12.2% YoY
Net Worth
₹16,300 Cr
+13.7% YoY
Total Assets
₹23,151 Cr
-0.4% YoY
Total Debt
₹6,312 Cr
-25.8% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue14,27812,20710,2608,7497,7826,2145,865
Revenue growth+17.0%+19.0%+17.3%+12.4%+25.2%+6.0%-
EBITDA3,4933,0202,5151,9021,9911,6491,438
EBITDA margin+24.5%+24.7%+24.5%+21.7%+25.6%+26.5%+24.5%
Profit before tax2,3332,5212,3991,6711,9751,6921,438
Net profit2,0141,7961,8071,2531,3691,217998
Net profit margin+14.1%+14.7%+17.6%+14.3%+17.6%+19.6%+17.0%
EPS (₹)1,913.0648.2547.7532.0035.7831.5925.72
Balance sheet
Total assets23,15123,2559,9297,9177,2905,1853,884
Net worth16,30014,3329,3637,4356,1554,7223,485
Total debt6,3128,511207170873241131
Cash & bank483554708453406701420
Net working capital2,3292,6052,3651,5311,7301,426976
Cash flow
Cash from operations3,1212,4132,1521,8139201,1371,070
Cash from investing(181)(12,624)(2,081)(1,052)(1,369)(1,222)(436)
Cash from financing(2,953)10,2335.27(740)605(7.81)(531)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue4,0313,4433,5673,6973,5703,0793,1993,061
Revenue growth (YoY)+12.9%+11.8%+11.5%+20.8%+24.5%---
Other income48.9411775.9694.1983.0525487.09112
EBITDA1,056907813921847679816845
EBITDA margin+26.2%+26.3%+22.8%+24.9%+23.7%+22.0%+25.5%+27.6%
Depreciation226223223222219231187100
Interest1101421571701711912217.10
Profit before tax769659509624540511495849
Tax19599.7595.1210495.8786.44110190
Net profit574559414520445425385659
EPS (₹)13.7413.419.8912.3810.6010.189.4416.28
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue10,4219,5078,6298,1277,4865,5304,794
Revenue growth+9.6%+10.2%+6.2%+8.6%+35.4%+15.3%-
EBITDA2,9802,4252,2671,6981,8381,3791,244
EBITDA margin+28.6%+25.5%+26.3%+20.9%+24.6%+24.9%+26.0%
Profit before tax2,3152,2082,2891,5631,8711,4401,265
Net profit2,1251,6051,7701,2191,3271,054940
Net profit margin+20.4%+16.9%+20.5%+15.0%+17.7%+19.1%+19.6%
EPS (₹)49.3643.2946.8331.1634.6827.0723.92
Balance sheet
Total assets22,19421,8379,8517,8987,3174,8983,715
Net worth16,39714,3239,7037,7846,5404,7343,651
Total debt5,5717,38323.504.696881012.56
Cash & bank159306484155139477198
Net working capital7035581,7911,0381,3611,212739
Cash flow
Cash from operations2,7522,3501,7361,7998211,022960
Cash from investing(388)(12,178)(1,665)(1,041)(1,360)(1,127)(396)
Cash from financing(2,477)9,816(4.73)(710)57988.87(559)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,9642,5822,6332,6092,5702,1192,4142,544
Revenue growth (YoY)+15.3%+21.8%+9.0%+2.5%+6.5%---
Other income33.9612756.5277.6765.2122070.37139
Total expenses2,0351,6861,9381,9161,8851,7781,6681,781
EBITDA929896695693685342746763
EBITDA margin+31.3%+34.7%+26.4%+26.6%+26.7%+16.1%+30.9%+30.0%
Depreciation11110910899.0310511591.1190.33
Interest94.951251381471491622002.61
Profit before tax757788505525496284525810
Tax19874.4056.4165.7380.9046.29113165

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 26 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue4,0313,4433,5673,6973,5703,0793,1993,061
Revenue growth (YoY)+12.9%+11.8%+11.5%+20.8%+24.5%---
Other income48.9411775.9694.1983.0525487.09112
EBITDA1,056907813921847679816845
EBITDA margin+26.2%+26.3%+22.8%+24.9%+23.7%+22.0%+25.5%+27.6%
Depreciation226223223222219231187100
Interest1101421571701711912217.10
Profit before tax769659509624540511495849
Tax19599.7595.1210495.8786.44110190
Net profit574559414520445425385659
EPS (₹)13.7413.419.8912.3810.6010.189.4416.28
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue14,27812,20710,2608,7497,7826,2145,865
Revenue growth+17.0%+19.0%+17.3%+12.4%+25.2%+6.0%-
Other income370554296141210183122
Total expenses10,7859,1877,7456,8485,7914,5654,427
Employee cost3,1842,6922,2611,9181,6211,4161,336
EBITDA3,4933,0202,5151,9021,9911,6491,438
EBITDA margin+24.5%+24.7%+24.5%+21.7%+25.6%+26.5%+24.5%
Depreciation88662137832616711999.06
Interest64443234.2445.7659.8021.1623.24
Profit before tax2,3332,5212,3991,6711,9751,6921,438
Tax395510457362522399382
Net profit2,0141,7961,8071,2531,3691,217998
Net profit margin+14.1%+14.7%+17.6%+14.3%+17.6%+19.6%+17.0%
EPS (₹)1,913.0648.2547.7532.0035.7831.5925.72
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital41.2841.2640.0640.0640.0640.0640.06
Reserves & surplus16,25914,2919,3237,3956,1154,6823,445
Shareholders' funds (net worth)16,30014,3329,3637,4356,1554,7223,485
Minority interest261236213188161141186
Secured loans5,7656,026196163804224114
Unsecured loans5472,48511.137.7368.7517.1416.68
Total debt6,3128,511207170873241131
Total liabilities23,15123,2559,9297,9177,2905,1853,884
Assets
Gross block21,37720,9175,9155,2394,2522,1661,993
Net block18,62019,0054,5454,2513,5881,6641,600
Capital work in progress1,128826282550701372317
Investments1,9852,0422,5681,3461,1091,512829
Inventories2,1442,0941,5531,4981,7601,184899
Sundry debtors1,7301,538848576388331531
Cash & bank balances483554708453406701420
Loans & advances1,0601,1111,200724978386307
Total current assets5,4175,2974,3103,2523,5322,6002,157
Total current liabilities3,0882,6921,9451,7211,8031,1751,181
Net working capital2,3292,6052,3651,5311,7301,426976
Total assets23,15123,2559,9297,9177,2905,1853,884
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash404382305283127220116
Net cash from operating activities3,1212,4132,1521,8139201,1371,070
Net cash from investing activities(181)(12,624)(2,081)(1,052)(1,369)(1,222)(436)
Net cash from financing activities(2,953)10,2335.27(740)605(7.81)(531)
Net change in cash(12.19)21.8777.1921.76156(92.40)103
Closing cash483554708453406701420
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+17.0%+19.0%+17.3%+12.4%+25.2%+6.0%-
EBITDA growth+15.6%+20.1%+32.2%-4.5%+20.7%+14.7%-
PBT growth-7.5%+5.1%+43.5%-15.4%+16.7%+17.7%+131.5%
Net income growth+12.2%-0.6%+44.2%-8.5%+12.5%+22.0%-
Revenue CAGR (3Y)+17.7%+16.2%+18.2%+14.3%+32.7%--
EBITDA CAGR (3Y)+22.5%+14.9%+15.1%+9.8%+50.3%--
Profitability & leverage
Net income margin+13.6%+16.5%+18.9%+15.0%+18.7%+20.8%+18.0%
Return on capital employed+13.0%+18.0%+27.9%+23.1%+33.4%+39.2%+39.5%
Return on net worth+12.7%+17.0%+23.1%+19.3%+26.7%+31.5%+30.3%
Debt / equity0.480.370.020.080.100.050.04
Long-term debt / equity0.280.240.000.010.010.010.01
Interest cover24.7218.001.602.903.281.381.74
Efficiency & per share
Fixed asset turnover0.680.911.841.842.432.992.94
Inventory turnover6.746.696.725.375.295.976.52
Debtors turnover8.7410.2314.4018.1421.6514.4211.04
EPS (₹)1,913.0648.2547.7532.0035.7831.5925.72
Dividend per share (₹)1.000.000.000.000.007.600.00
Book value per share (₹)16,301.46347.37233.73185.61153.65117.8887.00
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,9642,5822,6332,6092,5702,1192,4142,544
Revenue growth (YoY)+15.3%+21.8%+9.0%+2.5%+6.5%---
Other income33.9612756.5277.6765.2122070.37139
Total expenses2,0351,6861,9381,9161,8851,7781,6681,781
EBITDA929896695693685342746763
EBITDA margin+31.3%+34.7%+26.4%+26.6%+26.7%+16.1%+30.9%+30.0%
Depreciation11110910899.0310511591.1190.33
Interest94.951251381471491622002.61
Profit before tax757788505525496284525810
Tax19874.4056.4165.7380.9046.29113165
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue10,4219,5078,6298,1277,4865,5304,794
Revenue growth+9.6%+10.2%+6.2%+8.6%+35.4%+15.3%-
Other income32655537416320414893.85
Total expenses7,4417,0826,3626,4295,6484,1513,550
Employee cost2,3672,1491,9211,7011,4631,106991
EBITDA2,9802,4252,2671,6981,8381,3791,244
EBITDA margin+28.6%+25.5%+26.3%+20.9%+24.6%+24.9%+26.0%
Depreciation42939533527012378.1961.77
Interest56237816.9328.2347.548.2311.10
Profit before tax2,3152,2082,2891,5631,8711,4401,265
Tax277422413315482356307
Net profit2,1251,6051,7701,2191,3271,054940
Net profit margin+20.4%+16.9%+20.5%+15.0%+17.7%+19.1%+19.6%
EPS (₹)49.3643.2946.8331.1634.6827.0723.92
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital41.2841.2640.0640.0640.0640.0640.06
Reserves & surplus16,35614,2819,6637,7446,5004,6943,611
Shareholders' funds (net worth)16,39714,3239,7037,7846,5404,7343,651
Secured loans5,4885,44414.930.0062495.000.00
Unsecured loans82.521,9398.574.6964.235.852.56
Total debt5,5717,38323.504.696881012.56
Total liabilities22,19421,8379,8517,8987,3174,8983,715
Assets
Gross block5,8915,6584,5783,7763,2921,2271,117
Net block3,9264,0763,5523,1422,927987945
Capital work in progress420207209495387166148
Investments16,52316,6834,2153,1022,5262,3971,784
Inventories1,0881,0981,1261,0321,267827533
Sundry debtors1,164909769493471369419
Cash & bank balances159306484155139477198
Loans & advances7248491,0117751,071521404
Total current assets3,1353,1623,3902,4552,9472,1941,554
Total current liabilities2,4322,6041,5991,4181,586982816
Net working capital7035581,7911,0381,3611,212739
Total assets22,19421,8379,8517,8987,3174,8983,715
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash20121214586.1746.3677.5072.48
Net cash from operating activities2,7522,3501,7361,7998211,022960
Net cash from investing activities(388)(12,178)(1,665)(1,041)(1,360)(1,127)(396)
Net cash from financing activities(2,477)9,816(4.73)(710)57988.87(559)
Net change in cash(113)(10.96)66.1647.9639.81(15.96)5.02
Closing cash159306484155139477198
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+9.6%+10.2%+6.2%+8.6%+35.4%+15.3%-
EBITDA growth+22.9%+7.0%+33.5%-7.7%+33.4%+10.8%-
PBT growth+4.9%-3.5%+46.5%-16.5%+29.9%+13.9%+83.0%
Net income growth+32.4%-9.3%+45.2%-8.2%+25.9%+12.2%-
Revenue CAGR (3Y)+8.6%+8.3%+16.0%+19.2%+25.0%+12.2%+11.1%
EBITDA CAGR (3Y)+20.6%+9.7%+18.0%+10.9%+37.7%+21.0%+21.1%
Profitability & leverage
Net income margin+19.6%+18.8%+21.7%+15.4%+18.6%+19.6%+20.0%
Return on capital employed+13.1%+16.3%+23.4%+20.9%+31.4%+33.6%+36.4%
Return on net worth+13.3%+14.9%+20.3%+17.4%+24.7%+25.9%+28.5%
Debt / equity0.420.310.000.050.070.010.03
Long-term debt / equity0.250.210.000.000.000.000.00
Interest cover22.0518.590.881.982.770.630.94
Efficiency & per share
Fixed asset turnover1.801.862.072.303.314.724.77
Inventory turnover9.548.558.007.077.158.139.45
Debtors turnover10.0611.3313.6816.8717.8314.0417.19
EPS (₹)49.3643.2946.8331.1634.6827.0723.92
Dividend per share (₹)1.000.000.000.000.000.007.55
Book value per share (₹)397.21347.13242.21194.31163.27118.1891.15

Web traffic of Manforce Condoms

The website of Manforce Condoms (manforcecondoms.com) receives about 47.5K visits a month and ranks #794,700 among all websites worldwide, #3,849 in Sports Betting.

  • Monthly visits
    47.5K

    ▲ 56.2% vs previous month

  • Unique visitors
    19.8K

    per month

  • Global rank
    #794,700

    among all websites

  • Category rank
    #3,849

    Gambling · Sports Betting

Similar websites

Websites whose visitors overlap most with Manforce Condoms. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
YouTube
youtube.com
100%
30.4B#2View details
Facebook
facebook.com
71%
12.1B#3View details
epiclovestore.com
epiclovestore.com
60%
#1,293,284–
condompoint.com
condompoint.com
59%
–
HealthKart
healthkart.com
49%
1.4M#44,902View details
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Manforce Condoms

MANKIND: Q2 CONS NET PROFIT 7.1B RUPEES VS 5.11B (YOY); EST 6.15B
Exchange Update • today
MANKIND: Q2 REVENUE 43.4B RUPEES VS 36.97B (YOY)
Exchange Update • today
MANKIND: Q2 EBITDA 11.7B RUPEES VS 9.21B (YOY); Q2 EBITDA MARGIN 27% VS 24.92% (YOY)
Exchange Update • today
Mankind: Approves Merger Plan For Fully Owned Subsidiaries Prolijune Lifesciences And Pavi Buildwell.
Exchange Update • today
Mankind Pharma: Board Approves Investment of Up to €45 Million in Mankind Netherlands and Plans to Buy 70% Stake in Armed Cell Therapeutics for €48 Million.
Exchange Update • 11 days ago
MANKIND: Rs. 46.93 Crores BSE Block Trade; for ~ 196,108 Shares, at Rs. 2393.15
Exchange Update • 13 days ago
Mankind Pharma: Kotak Inst Eqt on Mankind Pharma Upgrades to Buy with Target Price of ₹3,000 as domestic business recovery accelerates with 14.6% YoY July/August sales growth, 120 bps outperformance versus IPM, improving market shares, stable field force, higher R&D and new launches, supporting ~23% FY26–29E EPS CAGR.
Exchange Update • 1 month ago
Mankind Pharma Ltd.: Rs. 28.49 Crores NSE Block Trade; for ~ 125,112 Shares, at Rs. 2276.90
Exchange Update • 1 month ago
Mankind Pharma: Gets ESG Rating Of 68.21 From Niche99 In Leader Category For FY26
Exchange Update • 1 month ago
Mankind Pharma Launches "Angdaan Mahadaan" to Inspire 1 Crore Indians to Pledge for Organ Donation
OdishaDiary • 1 month ago
Premium access

Complete news archive for Manforce Condoms

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Manforce Condoms

Manforce Condoms was founded in 2012.

Manforce Condoms is headquartered in Delhi, India. It is registered at Delhi, Delhi, India.

Manforce Condoms has 19,928 employees.

The primary company behind Manforce Condoms, Mankind Pharma Limited, reported revenue of ₹14,648 Cr for FY 2026, up 17% year on year.

Manforce is identified as a prominent condom brand in India, with sales data indicating widespread distribution and usage. Educational content on condom safety, usage guidelines, and related topics is provided through blogs and FAQs, which are accessed by users seeking reliable information. The brands products are marketed online and through retail channels, emphasizing prevention of unintended pregnancies and health risks. This approach is supported by expert advice and resources that address common concerns in sexual health, ensuring accessibility for consumers.

Manforce Condoms offers Condoms and Sexual Health Education.

Yes, Manforce Condoms is publicly traded on NSE under the ticker symbol MANKIND.

Manforce Condoms operates through Mankind Pharma Limited.

The legal entities of Manforce Condoms currently have 10 directors, including Rajeev Juneja, Sheetal Arora, Tilokchand Punamchand Ostwal and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available